
VitriVax
- VitriVax just raised $87M (Series C) on Nov 18
An innovative vaccine development and formulation technology company.
About
An innovative vaccine development and formulation technology company. VitriVax is an innovative vaccine development and formulation technology company focused on advancing vaccine candidates, including a Lyme disease vaccine candidate with a novel mechanism of action.
Where VitriVax is heading
Updated Nov 18, 2026, from 9 sources
VitriVax is a vaccine formulation company developing candidates for Lyme disease, rabies, polio, and other infectious diseases using a proprietary platform.vitrivaxbio.com Its recent record shows a step-by-step progression from early grants and a DoD contract toward equity financing aimed at bringing its Lyme disease vaccine into clinical trials.
vitrivaxbio.com
businesswire.com
Jul 2021
Raised a Series A to build out its vaccine formulation platform.
vitrivaxbio.com
Jul 2023
Received a $29M DoD contract to fund vaccine research.
vitrivaxbio.com
Dec 2024
Received a $3.6M grant for polio vaccine development, adding a second disease area to the pipeline.
vitrivaxbio.com
Apr 2025
Received a $5M CEPI grant for rabies vaccine development.
vitrivaxbio.com
Oct 2025
Raised $17.25M in Series B financing and secured a $9.9M manufacturing grant to scale clinical production.
vitrivaxbio.com
Nov 2026
Raised $87M in Series C financing to advance its Lyme disease vaccine candidate into clinical trials.
vitrivaxbio.com
businesswire.com
What it points to: Its recent financing record points to entering clinical trials with the Lyme disease vaccine candidate, with the $87M Series C providing the capital to do so.vitrivaxbio.com
businesswire.com
Signals agent
Reach companies that have budget right now
Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.
- Just raised a roundFresh budget, the week it lands
- Hiring sales and marketingGo-to-market roles mean money to spend
- Hiring fastA jump in open roles across the company
- In the newsLaunches and announcements worth a message
- The decision makerWho to contact, with a message you can edit
Is your startup an alternative to VitriVax?
People comparing tools land here. Get listed beside these.
Copy VitriVax's SEO strategy
How often they publish, which searches their posts chase and their newest posts. Then outrank them.
All funding rounds
Key facts
- Website
- vitrivaxbio.com
- Headquarters
- Boulder, Colorado, United States
- Employees
- 52
- Total funding
- $104M (Series C)
- Business model
- B2B
Funding rounds
- $87M18 Nov 2026Series CLargest round
Led by F-Prime, NEA, RA Capital, Sanofi Ventures
- $17M22 Oct 2025
Led by RA Capital
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 18 Nov 2026 | Series C | $87M | F-Prime, NEA, RA Capital, Sanofi Ventures |
| 22 Oct 2025 | Series B | $17M | RA Capital |
Tech stack
Detected on vitrivaxbio.com, last scanned 18 Nov 2026. Run your own scan
- Email provider
- Microsoft 365
Benchmarking
See how your site ranks against 16,849 startups
VitriVax sits in the 42nd percentile for Domain Rating. Check where yours lands, free.
Check your Domain RatingVitriVax has a Domain Rating of 34, the 42nd percentile of 16,849 startups we track.
Measured, not editorial
Ahrefs DR
Below median
Check yoursAgent Readiness
Below median
Scan yoursSite Speed
Below median
PageSpeedData Trust
Top 25%
Security
Click to scan
Agent Readiness
Can AI agents use your site?
VitriVax scores 37. Check yours free in a few seconds, or let Max Agent rerun it daily.
Run it daily with Max AgentGet notified when VitriVax changes
Used VitriVax? Write a review and get $5 in credits
Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:
- Email finder
- Market Map Maker
- Agent Readiness scans
- Deep intel
- Tech stack scans
Frequently asked
Is VitriVax growing?
Yes, fast. Our data shows it raised $87M in a Series C in November 2026, more than the $17M it raised in all the years before.
Who owns VitriVax?
VitriVax is privately held, owned by its founders and investors. RA Capital has backed 2 of the 2 rounds on record since October 2025, so it is likely among the largest outside shareholders. Exact stakes are not public.
Are there companies like VitriVax?
Yes. We list 8 companies like VitriVax, including Pfizer, Moderna and ImmunityBio.
Is VitriVax trustworthy and reputable?
StartupHub's Data Trust & Reputation score for VitriVax is 82 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has VitriVax raised?
VitriVax has raised a total of $104M in funding. The most recent round on record is Series C.
How many employees does VitriVax have?
VitriVax has approximately 52 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for VitriVax:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
Categories
Max Agent
Let Max Agent watch VitriVax and its market for you
New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.
Free week
Starter listings, once
AI answers checked
Daily for 7 days
ChatGPT
Perplexity
Max Agent
$79 a month, or $9.99 with our badge on your site
AI answers checked
Every week
ChatGPT
Claude
Perplexity
Gemini

